Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson is rather one of the companies that can be seen as a bond-like investment, generating returns not only via a coupon (dividend payments) but also by an increasing stock price.

However, we don’t see the data having an impact on either firm’s wide moat, given the very strong pipelines and product portfolios at both companies. Johnson & Johnson: Updated Guidance ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire the biopharmaceutical company for roughly $14.6 billion.

Johnson Controls International named Joakim Weidemanis as chief executive officer and lifted its 2025 profit forecast on ...

Key Takeaways Johnson Controls shares led the S&P 500's gainers Wednesday morning after the company's first-quarter results ...

Johnson, the founder and CEO of the Johnson Products Company (JPC), was one of the most successful Black entrepreneurs in America. After starting the Chicago-based, Black haircare company JPC with ...

Johnson & Johnson's financial results are generally steady and consistent. Check out the chart of revenue and net income below. The company's balance sheet is rock solid and has earned it an AAA ...